Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is a promising medical diagnostics technology company with strong potential for growth due to its innovative products, EsoCheck and EsoGuard, which have already received support from leading GI specialty associations. Though the company's current revenue is low, it is expected to increase significantly in the coming years and the recent Q4 results have exceeded expectations. With a strong balance sheet and plans for commercialization and regulatory approvals, Lucid is well-positioned for future success and its progress with Medicare is a potential catalyst for further growth. However, there are risks to consider, including liquidity concerns and the potential for product failure or regulatory hurdles.

Bears say

Lucid Diagnostics is poised for potential growth with the expected Medicare coverage of their EsoGuard product, but analysts still acknowledge the long road ahead for commercialization and growth in the billion dollar market potential. The recent Contractor Advisory Committee meeting and upcoming publication of the Draft LCD will likely help pave the way for mid-2026 coverage, but the risks associated with entering a crowded market should be closely considered.

Lucid Diagnostics (LUCD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.